Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL324 Target Snapshot

5-hydroxytryptamine receptor 2C · SINGLE PROTEIN · Rattus norvegicus

908Compounds
146Assays
14Approved Drugs
902.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P08909. Use UniProt P08909 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P08909 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 2C as ChEMBL target CHEMBL324, mapped to UniProt P08909. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 2C
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-14
ChEMBL target ID
CHEMBL324
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P08909
5-hydroxytryptamine receptor 2C
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5-hydroxytryptamine receptor 2C is the right protein anchor across sources, using UniProt P08909 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5-hydroxytryptamine receptor 2C
UniProt AccessionP08909
Component TypeProtein
Sequence Length460 aa

5-hydroxytryptamine receptor 2C

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as 5-hydroxytryptamine receptor 2C, mapped to UniProt P08909. Sequence length is 460 aa.

Mapped IDP08909
Review name5-hydroxytryptamine receptor 2C
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

14
Approved
4
Phase III
15
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC5046.0
KI801.0
EC5055.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL6706 9.96 Ki 0.11 Preclinical
CHEMBL3764539 9.81 Ki 0.156 Preclinical
CHEMBL111184 9.8 Ki 0.16 Preclinical
CHEMBL14563 9.8 Ki 0.16 Preclinical
CHEMBL324270 9.68 Ki 0.21 Preclinical
CHEMBL263083 9.6 Ki 0.25 Preclinical
CHEMBL6710 9.59 Ki 0.26 Preclinical
CHEMBL12314 9.43 Ki 0.37 Clinical
CHEMBL113238 9.41 Ki 0.39 Preclinical
CHEMBL7132 9.4 Ki 0.4 Preclinical
Distribution

pChEMBL Value Distribution

40
5.0
113
5.5
100
6.0
116
6.5
108
7.0
77
7.5
54
8.0
43
8.5
16
9.0
7
9.5
pChEMBL
Approved Drugs

Approved Drugs

ARIPIPRAZOLE
CHEMBL1112
Approved 2002
SERTINDOLE
CHEMBL12713
Approved 1996
MIRTAZAPINE
CHEMBL654
Approved 1996
RISPERIDONE
CHEMBL85
Approved 1993
CLOZAPINE
CHEMBL42
Approved 1989
FLUOXETINE
CHEMBL41
Approved 1987
BUSPIRONE
CHEMBL49
Approved 1986
LOXAPINE
CHEMBL831
Approved 1975
Assay Landscape

Assay Landscape

146
Total Assays
570
Tested Compounds
3
Assay Types
Binding — 130 assays, 570 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 59 204 6.8
assay format 26 148 7.0
cell-based format 18 138 6.8
tissue-based format 18 70 7.5
cell membrane format 9 10 7.2
Functional — 14 assays, 53 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 5 0
assay format 3 5 5.8
cell-based format 3 18 7.9
tissue-based format 3 30 6.0
ADME — 2 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 5 7.4
tissue-based format 1 4 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine